GlaxoSmithKline (GSK) has announced initial plans for a new UK-based headquarters site for its new Consumer Healthcare company as well as longer-term plans for a new headquarters site for all of GSK, which includes its pharma and vaccines businesses.

The proposals form part of GSK’s ongoing work to prepare for the separation of GSK into two separate companies in 2022: (1) the “new” GSK, which include the company’s global pharmaceuticals and vaccines businesses and (2) a separate Consumer Healthcare company with annual sales of more than £10 billion ($13 billion).

Under the proposals, the new Consumer Healthcare company will build a new campus in Weybridge, UK. This campus will house the global headquarters for the new Consumer Healthcare business, including an innovation center (made up of R&D laboratories and the Consumer Healthcare Shopper Science lab) and the company’s global support function teams based in the UK. It will be home to around 1,400 employees.

The new Consumer Healthcare company will open its new headquarters at the end of 2024, subject to consultation and planning approvals. While the development of the campus is ongoing, at the point of separation of the two companies, which is expected in mid-2022, Consumer Healthcare teams will leave GSK’s site in Brentford, UK and will move to a temporary headquarters in Weybridge, at a site close to, but separate from, the company’s existing facilities in the area.

Following separation, the “new” GSK focused on pharmaceuticals and vaccines will move to a new UK-based headquarters. The company says it will identify an appropriate site that meets the needs of the new organization with the search based in the same area as GSK’s current headquarters. GSK says it will provide a further update on its new headquarters in mid-2022, and expects to remain at the company’s current headquarters, at GSK’s site in Brentford, until at least the end of 2023.

Source: GlaxoSmithKline